Veit Schmelmer. Ph.D.
Vice President of Project Management and Portfolio Strategy

Dr. Veit Schmelmer is Vice President of Attovia, leading Project Management and Portfolio Strategy for the company. Veit has over 25 years of experience directing the development of novel therapies for cancer, autoimmune disorders, and infectious diseases at leading biopharmaceutical companies. Before joining Attovia, he was a Senior Vice President of Project and Alliance Management at Vor Bio where he oversaw the management of clinical research programs to advance the company’s engineered hematopoietic stem cell platform. Previously, he was a Vice President at Magenta Therapeutics where he directed the development of a novel biologic designed to mobilize stem cells. Prior, Veit held the position of Vice President of Portfolio Strategy at Mersana Therapeutics with responsibility for project leadership, alliance management, and portfolio strategy. Veit also served as Global Project Leader for Takeda with responsibility for global asset strategies for new pipeline projects, overseeing programs in oncology and immunology from late-stage discovery through approval. Notably, Veit directed the global development of Entyvio® through clinical development, MAA/BLA review, global approvals, and launch. Veit began his career at Boehringer Ingelheim where he held positions of increasing seniority in Germany, the U.S., and Japan.

Veit earned his Ph.D. in Pharmaceutical Technology and Biopharmaceutics from Heidelberg University. He is a board-certified pharmacist in Germany with a specialist degree in Pharmaceutical Technology.